DOCSLIB.ORG

The High NRF2 Expression Confers Chemotherapy Resistance Partly Through Up-Regulated DUSP1 in Myelodysplastic Syndromes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The High NRF2 Expression Confers Chemotherapy Resistance Partly Through Up-Regulated DUSP1 in Myelodysplastic Syndromes Myelodysplastic Syndromes SUPPLEMENTARY APPENDIX The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes Peipei Lin, 1,2,3,4 * Yanling Ren, 1,2,3 * Xiaomei Yan, 4 Yingwan Luo, 1,2,3 Hua Zhang, 1,2,3 Meenu Kesarwani, 4 Jiachen Bu, 4 Di Zhan, 4 Yile Zhou, 1,2,4 Yuting Tang, 4 Shuanghong Zhu, 1,2,3 Weilai Xu, 1,2,3 Xinping Zhou, 1,2,3 Chen Mei, 1,2,3 Liya Ma, 1,2,3 Li Ye, 1,2,3 Chao Hu, 1,2 Mohammad Azam, 4 Wei Ding, 5 Jie Jin, 1,2 Gang Huang 4# and Hongyan Tong 1,2,3# 1Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China; 2Institute of Hema - tology, Zhejiang University, Hangzhou, China; 3Myelodysplastic Syndromes Diagnosis and Therapy Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China; 4Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH, USA and 5Department of Pathology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China *PL and YR contributed equally to this work. #HYT and GH contributed equally to this study as joint senior authors. ©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.197749 Received: May 15, 2018. Accepted: September 26, 2018. Pre-published: September 27, 2018. Correspondence: HONGYAN TONG - [email protected] GANG HUANG - [email protected] Title: The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes Running title: NRF2 and Ara-C resistance in MDS Peipei Lin1,2,3,4*, Yanling Ren1,2,3*, Xiaomei Yan4, Yingwan Luo1,2,3, Hua Zhang1,2,3, Meenu Kesarwani4, Jiachen Bu4, Di Zhan4, Yile Zhou1,2,4, Yuting Tang4, Shuanghong Zhu1,2,3, Weilai Xu1,2,3, Xinping Zhou1,2,3, Chen Mei1,2,3, Liya Ma1,2,3, Li Ye1,2,3, Chao Hu1,2, Mohammad Azam4, Wei Ding5, Jie Jin1,2, Gang Huang4# and Hongyan Tong1,2,3# 1Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China 2Institute of Hematology, Zhejiang University, Hangzhou, China 3Myelodysplastic Syndromes Diagnosis and Therapy center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China 4Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA 5Department of Pathology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China *Statement of equal authors’ contribution: Peipei Lin and Yanling Ren contributed equally to this work. # HY.T. and G.H. contributed equally to this study as joint senior authors Corresponding Author: Hongyan Tong No.79 Qingchun Road, Hangzhou 310003, P.R. China Phone: +86-571-87236898, Fax: +86-571-87236702, Email: [email protected] Gang Huang 3333 Burnet Avenue, Room S7.224, Cincinnati, Ohio 45229-3039 Phone: (513) 636-3214, Fax: (513) 803-0783, Email: [email protected] Conflicts of Interest: The authors declare that they have no relevant conflicts of interest. Supplementary information • Supplementary Figure S1-S8 and Supplementary Figure Legends; • Supplementary Table S1-S6； • Supplementary Methods; • Supplemental List 1-3 A NRF2 induced genes B 0.3 0.2 The CD34 and NRF2 double positive cell in MDS 0.1 0.0 Enrichment score -0.1 MDS HC NES: 1.151 Normal p-value: 0.225 FDR q-value: 0.225 C CD34 NRF2 DAPI Merge #10 MDS-SLD #11 MDS-EB-1 #12 MDS-EB-2 Figure S1. (A) Gene set enrichment plot of NRF2 target genes in MDS patients and healthy controls (HC). (B) CD34 (red) and NRF2 (green) double-immunofluorescence staining in MDS. (C) Immunofluorescence results of CD34 (red), NRF2 (green) and DAPI (blue) staining in MDS patient samples (magnification ×400). PTD/WT A SKM-1 B MLL /RUNX1-S291fs 24h 150 24h 100 48h 48h n (%) 72h n (%) o io i t t 100 a r e era f f 50 li oli o r r P 50 P 0 0 2 3 4 5 1 2 3 4 5 lg [cytarabine(nM)] lg [cytarabine(nM)] C D SKM-1 SKM-1 Luteolin 0 μM 1.5 2.0 Sulforaphane 0 μM Luteolin 5 μM Sulforaphane 1 μM Luteolin 10 μM Sulforaphane 2.5 μM 1.5 1.0 1.0 0.5 0.5 NRF2 mRNA level NRF2 mRNA NRF2 mRNA level NRF2 mRNA 0.0 0.0 24 48 72 24 48 72 Time (h) Time (h) PTD/WT MLL /RUNX1-S291fs MLLPTD/WT /RUNX1-S291fs E Luteolin 0 μM F 1.5 2.0 Sulforaphane 0 μM Luteolin 1 μM Sulforaphane 1 μM 1.5 1.0 1.0 0.5 0.5 Nrf2 mRNA level Nrf2 mRNA Nrf2 mRNA level Nrf2 mRNA 0.0 0.0 24 48 24 48 Time (h) Time (h) Figure S2. Effects of Ara-C on proliferations of (A) SKM-1 and (B) MLLPTD/WT /RUNX1-S291fs cells lines. NRF2 mRNA levels of SKM-1 cells treated with (C) Luteolin and (D) Sulforaphane. Nrf2 mRNA levels of MLLPTD/WT /RUNX1-S291fs cells treated with (E) Luteolin and (F) Sulforaphane. A E SKM-1 SKM-1 150 24 h 24 h 150 48 h 48 h 72 h 72 h 100 100 50 50 Proliferation (%) Proliferation (%) 0 0 0 5 10 15 20 25 0 2 4 6 Luteolin (μM) Sulforaphane (μM) B F Luteolin (μM) Sulforaphane (μM) 24 h 0 1 5 10 24 h 0 0.5 1 2.5 Nrf2 Nrf2 β-actin β-actin Luteolin (μM) Sulforaphane (μM) 48 h 0 1 5 10 48 h 0 0.5 1 2.5 Nrf2 Nrf2 β-actin β-actin C G 24 h 150 24 h 100 48 h 48 h 100 50 50 Proliferation (%) Proliferation (%) 0 0 0 5 10 0 2 4 6 Luteolin (μM) Sulforaphane (μM) D H Sulforaphane 0 μM Luteolin 0 μM Sulforaphane 1 μM 100 Luteolin 1 μM 100 50 50 Proliferation (%) Proliferation (%) 0 0 1 2 3 4 5 1 2 3 4 lg [Ara-C (nM)] lg [Ara-C (nM)] Figure S3. (A) Lower concentrations of Luteolin had little effect on cell proliferation in SKM-1.(B) Luteolin decreased NRF2 protein levels in MLLPTD/WT /RUNX1-S291fs. (C) Lower concentrations of Luteolin had little effect on cell proliferation in MLLPTD/WT /RUNX1-S291fs. (D) Ara-C IC50 was significantly decreased by Luteolin in MLLPTD/WT /RUNX1-S291fs. (E) Lower concentrations of Sulforaphane had little effect on the proliferation in SKM-1. (F) Sulforaphane increased NRF2 protein levels in MLLPTD/WT /RUNX1-S291fs. (G) Lower concentrations of Sulforaphane had little effect on the proliferation in MLLPTD/WT /RUNX1-S291fs. (H) Ara-C IC50 was significantly increased by Sulforaphane treatment in MLLPTD/WT /RUNX1-S291fs. A B NRF2 Nrf2 Scramble shRNA Scramble shRNA 1.2 NRF2 shRNA 1.2 Nrf2 shRNA 1.0 1.0 0.8 0.8 0.6 0.6 0.4 0.4 mRNA level mRNA mRNA level mRNA 0.2 0.2 0.0 0.0 PTD/WT SKM-1 MLL /RUNX1-S291fs C D Scramble shRNANRF2 shRNA Scramble shRNANrf2 shRNA NRF2 Nrf2 1 0.6 1 0.2 β-actin β-actin 1 1.7 1 1.1 PTD/WT SKM-1 MLL /RUNX1-S291fs PTD/WT MLL /RUNX1-S291fs PTD/WT E F MLL /RUNX1-S291fs Scramble shRNA 40 Scramble shRNA 100 Nrf2 shRNA Nrf2 shRNA 30 20 50 10 Apoptotic Rate (%) Proliferation (%) 0 0 0 100 200 300 2 3 4 lg [Ara-C (nM)] Ara-C (nM) G H SKM-1 Scramble shRNA SKM-1 NRF2 shRNA-1 G0/G1 G0/G1 100 S 100 S G2/M G2/M 50 50 Percent of phase Percent of phase 0 0 0 0.5 1 1.5 0 0.5 1 1.5 Ara-C (μM) Ara-C (μM) PTD/WT I MLL /RUNX1-S291fs J MLLPTD/WT /RUNX1-S291fs Scramble shRNA Nrf2 shRNA-1 G0/G1 G0/G1 100 S 100 S G2/M G2/M 50 50 Percent of phase Percent of phase 0 0 0 100 200 300 0 100 200 300 Ara-C (nM) Ara-C (nM) Figure S4. NRF2 shRNA repressed NRF2 mRNA levels in ( A) SKM-1 cells and (B) MLLPTD/WT /RUNX1-S291fs. NRF2 shRNA repressed NRF2 protein levels in (C) SKM-1 cells and (D) MLLPTD/WT /RUNX1-S291fs. (E) NRF2 silencing significantly decreased IC50 of Ara-C in MLLPTD/WT /RUNX1-S291fs. (F) NRF2 shRNA enhanced apoptosis induced by Ara-C in MLLPTD/WT /RUNX1-S291fs. (G-J) NRF2 shRNA induced S phrase arrest in SKM-1 and MLLPTD/WT /RUNX1-S291fs treated by Ara-C. PTD/WT A SKM-1 B MLL /RUNX1-S291fs 10 Control Control 15 ** ** SFN 1 μM (24h) SFN 2.5 uM (72h) ls ls 8 ** eve eve l l 6 10 ** 4 mRNA mRNA 5 ** ** 2 ** * 0 0 1 M lm p L c s QO1 C Nrf2 u NRF2 HO-1 Nqo1 Ho-1 G N G DUSP1 D C D SKM-1 MLLPTD/WT/RUNX1-S291fs 1.5 Scramble shRNA Scramble shRNA 1.5 s NRF2 shRNA s l Nrf2 shRNA l 1.0 eve eve l 1.0 l * * * 0.5 * * mRNA 0.5 mRNA ** 0.0 0.0 M 1 L lm p QO1 c s HO-1 C Nrf2 Nqo1 Ho-1 G u NRF2 N G DUSP1 D E PTD/WT 120 MLL /RUNX1-S291fs Control 100 SFN 1 μM 80 60 40 % survuval fraction (48h) M) M) μ μ BCI (1 No treatment Ara-C (0.15 Ara-C+BCI_predicted Ara-C+BCI_experimental Figure S5.
Load more

Recommended publications
  • The CLN5 Disease
    Mia-Lisa Schmiedt Mia-Lisa Schmiedt Mia-Lisa Schmiedt The CLN5 disease − RESEARCH protein maturation, RESEARCH The CLN5 disease − protein maturation, trafficking and pathology trafficking and pathology The CLN5 disease −protein maturation, trafficking and pathology and trafficking maturation, The CLN5 disease −protein Neuronal ceroid lipofuscinoses (NCLs) are a group of hereditary neurode- generative disorders primarily affecting children. Characteristics for NCLs are accumulation of autofluorescent storage material, neuronal degenera- tion, motor disturbances, progressive loss of vision and premature death. One member of the NCL family is the CLN5 disease, a late infantile variant phenotype form, caused by mutations in the CLN5 gene. CLN5 encodes a lysosomal protein of unidentified function. This thesis work contributes to the basic understanding of the molecular and cell biological mechanisms underlying CLN5 disease. Real-time PCR studies indicated that Cln5 gene expression increases gradually in the mouse brain with age and its expres- sion is highest in microglia. This thesis project further presents that the CLN5 protein is cleaved in the ER, trimmed and finally traffics to lysosomes. CLN5 constructs carrying different disease causing mutations revealed that trafficking is disturbed with varying severity depending on the particular mutation. Also, this work provides novel aspects about the early events in the pathogenesis of CLN5 disease, late infantile variant, links Cln5 to lipid metabolism and strengthens the recently reported
    [Show full text]
  • Effect of Distinct Regulator of G-Protein Signaling 10 Isoforms On
    EFFECT OF DISTINCT REGULATOR OF G-PROTEIN SIGNALING 10 ISOFORMS ON CYTOKINE PRODUCTION. by BENJAMIN JACKWOOD (Under the Direction of Shelley Hooks) ABSTRACT G-protein coupled receptors (GPCRs) mediate a wide variety of cellular functions related to cell proliferation and survival. Regulators of G-protein Signaling (RGS) proteins that are important negative regulators of both G-proteins and GPCR products. The focus of this thesis involves two human protein variants of RGS10 and their effects on cytokine levels. RGS proteins are GTPase Accelerating Proteins (GAPs) which can facilitate an increased rate of GTP hydrolysis to drive inactivation of GPCR signaling. Based on their ability to regulate GPCRs, RGS proteins are implicated in multiple disease states including cancer and neuro-inflammation. The aim of this study was to define the similarities or differences among RGS10 protein isoforms, and help understand their non-canonical function. Particularly, differences in primary sequence of RGS10 protein variants and their ability to mediate inflammatory cytokines in human embryonic kidney (HEK) cells was investigated. INDEX WORDS: GPCR, RGS10, ISOFORM, TNF-, INFLAMMATION, VARIANTS EFFECT OF DISTINCT REGULATOR OF G-PROTEIN SIGNALING 10 ISOFORMS ON CYTOKINE PRODUCTION. by BENJAMIN JACKWOOD BS, University of North Georgia, 2015 A Thesis Submitted to the Pharmaceutical and Biomedical Sciences department of The University of Georgia in Partial Fulfillment of the Requirements for the Degree. MASTER OF SCIENCE ATHENS, GEORGIA 2017 © 2017 Benjamin Jackwood All Rights Reserved EFFECT OF DISTINCT REGULATOR OF G-PROTEIN RGS10 ISOFORMS ON CYTOKINE PRODUCTION. by BENJAMIN JACKWOOD Major Professor: Shelley B. Hooks Committee: Phillip Greenspan Jason Zastre Electronic Version Approved: Suzanne Barbour Dean of the Graduate School The University of Georgia May 2017 ACKNOWLEDGEMENTS Thanks to my family, friends, and helpful lab mates for all of their support during my time working and studying at the University of Georgia.
    [Show full text]
  • Machine-Learning and Chemicogenomics Approach Defi Nes and Predicts Cross-Talk of Hippo and MAPK Pathways
    Published OnlineFirst November 18, 2020; DOI: 10.1158/2159-8290.CD-20-0706 RESEARCH ARTICLE Machine -Learning and Chemicogenomics Approach Defi nes and Predicts Cross-Talk of Hippo and MAPK Pathways Trang H. Pham 1 , Thijs J. Hagenbeek 1 , Ho-June Lee 1 , Jason Li 2 , Christopher M. Rose 3 , Eva Lin 1 , Mamie Yu 1 , Scott E. Martin1 , Robert Piskol 2 , Jennifer A. Lacap 4 , Deepak Sampath 4 , Victoria C. Pham 3 , Zora Modrusan 5 , Jennie R. Lill3 , Christiaan Klijn 2 , Shiva Malek 1 , Matthew T. Chang 2 , and Anwesha Dey 1 ABSTRACT Hippo pathway dysregulation occurs in multiple cancers through genetic and non- genetic alterations, resulting in translocation of YAP to the nucleus and activation of the TEAD family of transcription factors. Unlike other oncogenic pathways such as RAS, defi ning tumors that are Hippo pathway–dependent is far more complex due to the lack of hotspot genetic alterations. Here, we developed a machine-learning framework to identify a robust, cancer type–agnostic gene expression signature to quantitate Hippo pathway activity and cross-talk as well as predict YAP/TEAD dependency across cancers. Further, through chemical genetic interaction screens and multiomics analyses, we discover a direct interaction between MAPK signaling and TEAD stability such that knockdown of YAP combined with MEK inhibition results in robust inhibition of tumor cell growth in Hippo dysregulated tumors. This multifaceted approach underscores how computational models combined with experimental studies can inform precision medicine approaches including predictive diagnostics and combination strategies. SIGNIFICANCE: An integrated chemicogenomics strategy was developed to identify a lineage- independent signature for the Hippo pathway in cancers.
    [Show full text]
  • Gene Expression-Based Recurrence Prediction of Hepatitis B Virus-Related Human Hepatocellular Carcinoma
    GSK 후원 해외연수지원 기금 연구보고 Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma Yoon Jun Kim, M.D. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea ABSTRACT Hepatocellular carcinoma (HCC) is one of poor prognostic malignancies because of the high rate of recurrence even after curative resection of tumors. To predict and classify the molecular signatures associated with early recurrence, we profiled the gene expression of 65 HCC samples with hepatitis B infection using genome-scale oligonucleotide microarray. We identified 348 unique gene set well reflecting early recurrence (ER) of HCC, which revealed to be enriched by GTPase signaling related genes, transcription, immune response, cell adhesion and motility related genes. We also generated a signature responding to recurrence time by using Cox proportional hazard model (HR genes). Hierarchical clustering showed that HR genes are more accurate classifier than ER genes. In addition, we applied a meta-analysis to integrate earlier expression data (Iizuka et al, 2003), and obtained 232 genes consistently expressed in both the independent data. This signature was validated in an independent study indicating its robustness for the prediction of HCC recurrence. In conclusion, the gene signatures retrieved from different but complementary methods may provide clues to predict patients with increased risk of developing early recurrence, and to identify novel therapeutic targets for HCC. Key Words: Hepatitis B Virus; Hepatocellular carcinoma; Recurrence; Microarray; Gene Expression Profile Corresponding Author: Yoon Jun Kim, Department of Internal Medicine, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea.
    [Show full text]
  • An Extracellular Site on Tetraspanin CD151 Determines Α3 and Α6
    JCBArticle An extracellular site on tetraspanin CD151 determines ␣3 and ␣6 integrin–dependent cellular morphology Alexander R. Kazarov, Xiuwei Yang, Christopher S. Stipp, Bantoo Sehgal, and Martin E. Hemler Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, MA 02115 he ␣3␤1 integrin shows strong, stoichiometric, direct Brij 96–resistant) were independent of the QRD/TS151r lateral association with the tetraspanin CD151. As site, occurred late in biosynthesis, and involved mature T shown here, an extracellular CD151 site (QRD194–196) integrin subunits. Presence of the CD151–QRD194–196→INF is required for strong (i.e., Triton X-100–resistant) ␣3␤1 mutant disrupted ␣3 and ␣6 integrin–dependent formation association and for maintenance of a key CD151 epitope of a network of cellular cables by Cos7 or NIH3T3 cells on (defined by monoclonal antibody TS151r) that is blocked basement membrane Matrigel and markedly altered cell upon ␣3 integrin association. Strong CD151 association spreading. These results provide definitive evidence that with integrin ␣6␤1 also required the QRD194–196 site and strong lateral CD151–integrin association is functionally masked the TS151r epitope. For both ␣3 and ␣6 integrins, important, identify CD151 as a key player during ␣3 and strong QRD/TS151r-dependent CD151 association occurred ␣6 integrin–dependent matrix remodeling and cell spreading, early in biosynthesis and involved ␣ subunit precursor and support a model of CD151 as a transmembrane linker forms. In contrast, weaker associations of CD151 with itself, between extracellular integrin domains and intracellular integrins, or other tetraspanins (Triton X-100–sensitive but cytoskeleton/signaling molecules.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Palmitoyl-Protein Thioesterase 1 Deficiency in Drosophila Melanogaster Causes Accumulation
    Genetics: Published Articles Ahead of Print, published on February 1, 2006 as 10.1534/genetics.105.053306 Palmitoyl-protein thioesterase 1 deficiency in Drosophila melanogaster causes accumulation of abnormal storage material and reduced lifespan Anthony J. Hickey*,†,1, Heather L. Chotkowski*, Navjot Singh*, Jeffrey G. Ault*, Christopher A. Korey‡,2, Marcy E. MacDonald‡, and Robert L. Glaser*,†,3 * Wadsworth Center, New York State Department of Health, Albany, NY 12201-2002 † Department of Biomedical Sciences, State University of New York, Albany, NY 12201-0509 ‡ Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114 1 current address: Albany Medical College, Albany, NY 12208 2 current address: Department of Biology, College of Charleston, Charleston, SC 294243 3 corresponding author: Wadsworth Center, NYS Dept. Health, P. O. Box 22002, Albany, NY 12201-2002 E-mail: [email protected] 1 running title: Phenotypes of Ppt1-deficient Drosophila key words: Batten disease infantile neuronal ceroid lipofuscinosis palmitoyl-protein thioesterase CLN1 Drosophila corresponding author: Robert L. Glaser Wadsworth Center, NYS Dept. Health P. O. Box 22002 Albany, NY 12201-2002 E-mail: [email protected] phone: 518-473-4201 fax: 518-474-3181 2 ABSTRACT Human neuronal ceroid lipofuscinoses (NCLs) are a group of genetic neurodegenerative diseases characterized by progressive death of neurons in the central nervous system (CNS) and accumulation of abnormal lysosomal storage material. Infantile NCL (INCL), the most severe form of NCL, is caused by mutations in the Ppt1 gene, which encodes the lysosomal enzyme palmitoyl-protein thioesterase 1 (Ppt1). We generated mutations in the Ppt1 ortholog of Drosophila melanogaster in order to characterize phenotypes caused by Ppt1-deficiency in flies.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Enhanced Phosphorylation of High-Mobility-Group Proteins In
    Proc. Nati. Acad. Sci. USA Vol. 78, No. 4, pp. 2189-2193, April 1981 Biochemistry Enhanced phosphorylation of high-mobility-group proteins in nuclease-sensitive mononucleosomes from butyrate-treated HeLa cells (hyperphosphorylation/transcriptionally active chromatin/sodium butyrate) BEATRIZ LEVY-WILSON Department of Molecular Biology and Biochemistry, University of California, Irvine, California 92717 Communicated by James F. Bonner, December 29, 1980 ABSTRACT The protein composition of nucleosome fractions MATERIALS AND METHODS differing in their sensitivity to micrococcal nuclease and derived from butyrate-treated or untreated HeLa cells has been com- Cell Cultures. HeLa cells, line S3, were grown in monolay- pared. Most of the high-mobility-group-14 (HMG-14) and HMG- ers, either in T-150 culture flasks or in roller bottles, at 370C 17 content of HeLa cell chromatin is associated with those nu- in minimal essential medium (Flow Laboratories, Rockville, cleosomes that are preferentially sensitive to micrococcal nu- MD) supplemented with 7% bovine calfserum (KC Biologicals) clease. Furthermore, electrophoresis of these two HMG proteins and penicillin (100 units/ml) and streptomycin (100 Ag/ml) from the transcriptionally active chromatin fraction MN, of bu- (Sigma). In experiments involving sodium butyrate, this com- tyrate-treated cells resolves them into a series ofbands. The mul- pound was added to the cultures at a final concentration of5 mM tiple band pattern of HMG-14 and -17 from butyrate-treated cells about 20 hr prior to harvesting of the cells. results from hyperphosphorylation rather than hyperacetylation. Preparation of Nuclei. HeLa cell nuclei were prepared as Phosphorylation of these two small nonhistone proteins may play described by Milcarek et al.
    [Show full text]
  • Page 1 Supplemental Table I Upin WTVG Upin Humlowfb FAR1
    Supplemental Table I UPinWTvG UPinHuMlowFB overlap FAR1 CD209 PLEKHO2 B2M IL27 GCLC CALR HMGN2P46 ME1 XPO1 CLEC1A NEK6 PDIA3 HSD17B14 TMEM106A SERPINH1 NSUN7 KCNJ15 PLEKHO2 SEMA6B SH3PXD2B HSPD1 BAALC RHOU SYVN1 CEACAM4 TGFBI DNAJB9 KATNAL2 CTSZ SLC25A19 CCDC175 SULF2 MHCII CARD14 P2RY6 MDN1 TDO2 CD74 GCLC FCAR HLA-DQB1 PTPN2 GLDN CD14 CHORDC1 MMP7 CSF2RB LOX CLEC5A MRC1 STIP1 ZMYND15 ITGAX BPIFB1 ITLN1 SLAMF7 ME1 DKK2 CD84 PDIA6 FAM124A FCGR2A HYOU1 F3 CLEC10A NLRC5 DZIP1L IFI30 NEK6 CECR6 CLEC4A SLC39A14 NDP CLEC7A TMEM106AFCGR1A TFEC KCNJ15 CCL7 C1QC SH3PXD2B CRABP2 C1QA RHOU PIPOX FOLR2 LRP2 CCL2 CH25H MVD VSIG4 C1QB TGFBI LINC01010 SIGLEC1 NFKB2 DPRXP4 CTSS C5 FAM20A CCR1 HSP90B1 ANKRD29 SLAMF8 ALDH18A1 OCSTAMP MS4A7 EDEM1 TGM2 HK3 CTSZ TM4SF19 CXCL10 C6 TRPV4 CTSK AACS CCL8 MSR1 PPA1 CCL1 STEAP4 PIK3R5 KCNE1 CXCL9 RASAL3 SLC9A7P1 MS4A6A DOCK11 CHI3L1 TIMP1 BHLHE40 LOC731424 CD209 HCLS1 DCSTAMP CCL7 FASN MSR1 PDCD1LG2 PDIA4 IL31RA CCL2 ITK CXCL3 CXCL2 CRELD2 TREM2 C15orf48 SFTPD MGST1 GPR84 BCL3 METTL7B CXCL5 SULF2 TMEM86A OCSTAMP CYP51A1 A2M SERPINA1 CREB3L1 AQP9 MMP12 DUSP2 NUPR1 CCL8 ADAM8 FHAD1 CCL24 P2RY6 YPEL4 FBP1 KCNAB2 FBP1 NA NFKBIE LOC100506585 NA FSCN1 CXCL16 NA MANF RAB13 NA SLC5A3 LOC391322 NA CTSC IL8 NA COTL1 MS4A4A NA HSPA5 SERPING1 NA MUC5B PLA2G4C NA CD74 CA12 NA HLA-DQB1 GBP1P1 NA SLC7A2 C11orf45 NA FABP5 ACVRL1 NA CIITA SPP1 NA RAB3IL1 TLN2 NA HSPE1 NDRG2 NA SCD C15orf48 NA ITIH4 KCNJ15 NA SERPINA3 MEIS3P1 NA LAG3 IL1RN NA FOXM1 HNMT NA CD14 CYP27B1 NA RRM2 CDCP1 NA ABCD2 FOLR2 NA FCRL2 ECM1 NA PDE3B ADAMDEC1
    [Show full text]
  • PRODUCT SPECIFICATION Anti-TSPAN3
    Anti-TSPAN3 Product Datasheet Polyclonal Antibody PRODUCT SPECIFICATION Product Name Anti-TSPAN3 Product Number HPA015996 Gene Description tetraspanin 3 Clonality Polyclonal Isotype IgG Host Rabbit Antigen Sequence Recombinant Protein Epitope Signature Tag (PrEST) antigen sequence: NGTNPDAASRAIDYVQRQLHCCGIHNYSDWENTDWFKETKNQSVPLSCCR ETASNCNGSLAHPSDLYAEGCEALVVKKLQEI Purification Method Affinity purified using the PrEST antigen as affinity ligand Verified Species Human Reactivity Recommended IHC (Immunohistochemistry) Applications - Antibody dilution: 1:20 - 1:50 - Retrieval method: HIER pH6 ICC-IF (Immunofluorescence) - Fixation/Permeabilization: PFA/Triton X-100 - Working concentration: 0.25-2 µg/ml Characterization Data Available at atlasantibodies.com/products/HPA015996 Buffer 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative. Concentration Lot dependent Storage Store at +4°C for short term storage. Long time storage is recommended at -20°C. Notes Gently mix before use. Optimal concentrations and conditions for each application should be determined by the user. For protocols, additional product information, such as images and references, see atlasantibodies.com. Product of Sweden. For research use only. Not intended for pharmaceutical development, diagnostic, therapeutic or any in vivo use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB. Warranty: The products supplied by Atlas Antibodies are warranted to meet stated product specifications and to conform to label descriptions when used and stored properly. Unless otherwise stated, this warranty is limited to one year from date of sales for products used, handled and stored according to Atlas Antibodies AB's instructions. Atlas Antibodies AB's sole liability is limited to replacement of the product or refund of the purchase price.
    [Show full text]
  • Termin Translat Trna Utr Mutat Protein Signal
    Drugs & Chemicals 1: Tumor Suppressor Protein p53 2: Heterogeneous-Nuclear Ribonucleo- (1029) proteins (14) activ apoptosi arf cell express function inactiv induc altern assai associ bind mdm2 mutat p53 p73 pathwai protein regul complex detect exon famili genom respons suppress suppressor tumor wild-typ interact intron isoform nuclear protein sensit site specif splice suggest variant 3: RNA, Transfer (110) 4: DNA Primers (1987) codon contain differ eukaryot gene initi amplifi analysi chain clone detect dna express mrna protein region ribosom rna fragment gene genotyp mutat pcr sequenc site speci suggest synthesi polymorph popul primer reaction region restrict sequenc speci termin translat trna utr 5: Saccharomyces cerevisiae Proteins 6: Apoptosis Regulatory Proteins (291) (733) activ apoptosi apoptosis-induc albican bud candida cerevisia complex encod apoptot bcl-2 caspas caspase-8 cell eukaryot fission function growth interact involv death fasl induc induct ligand methyl necrosi pathwai program sensit surviv trail mutant pomb protein requir saccharomyc strain suggest yeast 7: Plant Proteins (414) 8: Membrane Proteins (1608) access arabidopsi cultivar flower hybrid leaf leav apoptosi cell conserv domain express function gene human identifi inhibitor line maiz plant pollen rice root seed mammalian membran mice mous mutant seedl speci thaliana tomato transgen wheat mutat protein signal suggest transport 1 9: Tumor Suppressor Proteins (815) 10: 1-Phosphatidylinositol 3-Kinase activ arrest cell cycl cyclin damag delet dna (441) 3-kinas activ
    [Show full text]